These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 19112963)

  • 1. [Role of pemetrexed in the treatment of advanced non-small-cell lung cancer: news from ASCO, 2008].
    de Marinis F; Ricciardi S
    Tumori; 2008; 94(5):suppl 3-13. PubMed ID: 19112963
    [No Abstract]   [Full Text] [Related]  

  • 2. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
    Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
    [No Abstract]   [Full Text] [Related]  

  • 3. [Study of use of pemetrexed in non-small cell lung cancer].
    Villanueva-Herraiz S; Ortega-García MP; Camps-Herrero C; Blasco-Segura P
    Farm Hosp; 2010; 34(4):194-203. PubMed ID: 20594885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed in advanced non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A; Bareschino MA; Schettino C; Sacco PC; Zeppa R
    Expert Opin Drug Saf; 2011 Mar; 10(2):311-7. PubMed ID: 21261558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
    Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
    Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
    Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer.
    Schiller JH; von Pawel J; Schütt P; Ansari RH; Thomas M; Saleh M; McCroskey RD; Pfeifer W; Marsland TA; Kloecker GH; Sebastian M; Pirker R; Kurek R; Beadman C; Socinski MA
    J Thorac Oncol; 2010 Dec; 5(12):1977-85. PubMed ID: 20978446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
    Yu YF; Chen ZW; Zhou Z; Song ZB; Li ZM; Jian H; Zhang YF; Lu S
    Chemotherapy; 2010; 56(6):472-7. PubMed ID: 21099219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
    Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A
    J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
    J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.
    Malhotra B; Evans T; Weiss J; Eaby B; Stonehouse-Lee S; Sherry V; Langer CJ
    Clin Lung Cancer; 2010 May; 11(3):192-7. PubMed ID: 20439196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089).
    Rittmeyer A; Gorbunova V; Vikström A; Scherpereel A; Kim JH; Ahn MJ; Chella A; Chouaid C; Campbell AK; Barlesi F
    J Thorac Oncol; 2013 Nov; 8(11):1409-16. PubMed ID: 24077452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
    Kubota K; Niho S; Enatsu S; Nambu Y; Nishiwaki Y; Saijo N; Fukuoka M
    J Thorac Oncol; 2009 Dec; 4(12):1530-6. PubMed ID: 19755925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype.
    Tiseo M; Bartolotti M; Gelsomino F; Ardizzoni A
    Expert Rev Anticancer Ther; 2009 Apr; 9(4):425-35. PubMed ID: 19374597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum-Vinorelbine Induction Chemotherapy plus Bevacizumab With and Without Pemetrexed Switch Maintenance in Advanced NSCLC.
    Michelsen L; Sørensen JB
    Anticancer Res; 2015 Nov; 35(11):6255-9. PubMed ID: 26504059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pemetrexed: a review of its use in the management of advanced non-squamous non-small cell lung cancer.
    Baldwin CM; Perry CM
    Drugs; 2009 Nov; 69(16):2279-302. PubMed ID: 19852529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed plus bevacizumab for second-line therapy of non-small-cell lung cancer: the importance of patient selection.
    Araujo AM
    J Clin Oncol; 2010 Mar; 28(8):e131; author reply e132. PubMed ID: 20100954
    [No Abstract]   [Full Text] [Related]  

  • 20. Pemetrexed and maintenance therapy for non-small cell lung cancer.
    Prescrire Int; 2011 Feb; 20(113):39. PubMed ID: 21488588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.